



Aldeyra to Present at Cantor and H.C. Wainwright Virtual Investor Conferences

September 10, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Sep. 10, 2020-- [Aldeyra Therapeutics, Inc.](#) (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting one-on-one meetings at the following investor conferences:

- **H.C. Wainwright 22nd Annual Global Investment Conference**

Presentation Date: Monday, September 14, 2020

Time: 3:30 p.m. ET

- **2020 Cantor Global Virtual Healthcare Conference**

Presentation Date: Wednesday, September 16, 2020 (Fireside Chat)

Time: 2:40 p.m. ET

A live webcast of the presentations will be available on the investor relations page of the company's corporate website at <https://ir.aldeyra.com>. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF- κ B, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200910005197/en/): <https://www.businesswire.com/news/home/20200910005197/en/>

Corporate Contact:

David McMullin

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

dmcullin@aldeyra.com

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Source: Aldeyra Therapeutics, Inc.